Intravenous bisphosphonate-associated osteonecrosis of the jaw

Journal of Periodontology

Volumn 78, Issue 11, 2007, Pages 2203-2208

  Statz, Thomas A ^a   Guthmiller, Janet M ^a   Humbert, Lewis A ^a   Johnson, Georgia K ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Bisphosphonates; Multiple myeloma; Osteonecrosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

AGED; ARTICLE; BONE NECROSIS; CASE REPORT; CHEMICALLY INDUCED DISORDER; HUMAN; JAW DISEASE; MALE; MANDIBLE FRACTURE; MULTIPLE MYELOMA; RADIOGRAPHY;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; JAW DISEASES; MALE; MANDIBULAR FRACTURES; MULTIPLE MYELOMA; OSTEONECROSIS;

EID: 36348999724     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2007.070104     Document Type: Article

References (22)

1. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-3736.
2. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000;18:1378-1391.
3. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 2005;23:8219-8224.
4. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-34.
5. Green JR. Bisphosphonates: Preclinical review. Oncologist 2004;9(Suppl. 4):3-13.
6. Heymann D, Ory B, Gouin F, Green JR, Redini F. Bisphosphonates: New therapeutic agents for the treatment of bone tumors. Trends Mol Med 2004;10:337-343.
7. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907.
8. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
9. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61: 1115-1117.
10. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761.
11. American Dental Association Report of the Council of Scientific Affairs. Expert panel recommendations: Dental management of patients on oral bisphosphonate therapy. J Am Dent Assoc 2006;137:1144-1150.
12. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005;23:8580-8587.
13. Hoff AO, Toth BB, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol [serial online]. 2006; 24:8528. Available from: http://meeting.jco.org/cgi/ content/abstract/24/18_suppl/8528. Accessed January 31, 2007.
14. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136:1658-1668.
15. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: Strategies for prevention and early recognition. J Am Dent Assoc 2005;136:1675-1681.
16. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353: 99-102.
17. Van den Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: Cause and effect or a post hoc fallacy? Ann Oncol 2006; 17:1197-1204.
18. Longo DL, Anderson KC. Plasma cell disorders. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, eds. Harrison's Principles of Internal Medicine. New York: McGraw Hill; 2005:656-661.
19. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/ osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575.
20. Hellstein JW, Marek CL. Bisphosphonate induced osteochemonecrosis of the jaws: An ounce of prevention may be worth a pound of cure. Spec Care Dentist 2006;26:8-12.
21. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. Available at: http://www.aaoms. org/docs/position_papers/osteonecrosis.pdf. Accessed January 31, 2007.
22. American Academy of Periodontology. AAP Statement on Bisphosphonates. Available at: http://www.perio. org/resources-products/bisphosphonates.htm. Accessed October 17, 2007.